Details of the Drug

General Information of Drug (ID: DMXCM7H)

Drug Name
Cerivastatin
Synonyms
cerivastatin; Baycol; cerivastatin acid; Lipobay; 145599-86-6; Cerivastatin [INN:BAN]; UNII-AM91H2KS67; CHEBI:3558; AM91H2KS67; HSDB 7357; (3R,5S,6E)-7-(4-(p-Fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)-3-pyridyl)-3,5-dihydroxy-6-heptenoic acid; (3R,5S,6E)-7-(4-(4-Fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-6-heptenoic acid; 143201-11-0; 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-, (3R,5S,6E)-; Statins
Indication
Disease Entry ICD 11 Status REF
Hyperlipidaemia 5C80 Approved [1]
Multiple myeloma 2A83 Phase 1/2 [2]
Affected Organisms
Humans and other mammals
ATC Code
C10AA06: Cerivastatin
C10AA: HMG CoA reductase inhibitors
C10A: LIPID MODIFYING AGENTS, PLAIN
C10: LIPID MODIFYING AGENTS
C: CARDIOVASCULAR SYSTEM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 459.5
Logarithm of the Partition Coefficient (xlogp) 3.6
Rotatable Bond Count (rotbonds) 11
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 7
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability
The bioavailability of drug is 60% []
Clearance
The drug present in the plasma can be removed from the body at the rate of 2.9 mL/min/kg [4]
Elimination
24% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 2 - 3 hours [4]
Metabolism
The drug is metabolized via the hepatic []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.01088 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.01% [4]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.33 L/kg [4]
Water Solubility
The ability of drug to dissolve in water is measured as 195 mg/mL [3]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Rhabdomyolysis rs2819742 RYR2 OT0PF19E [6]
Chemical Identifiers
Formula
C26H34FNO5
IUPAC Name
(E,3R,5S)-7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-di(propan-2-yl)pyridin-3-yl]-3,5-dihydroxyhept-6-enoic acid
Canonical SMILES
CC(C)C1=C(C(=C(C(=N1)C(C)C)COC)C2=CC=C(C=C2)F)/C=C/[C@H](C[C@H](CC(=O)O)O)O
InChI
InChI=1S/C26H34FNO5/c1-15(2)25-21(11-10-19(29)12-20(30)13-23(31)32)24(17-6-8-18(27)9-7-17)22(14-33-5)26(28-25)16(3)4/h6-11,15-16,19-20,29-30H,12-14H2,1-5H3,(H,31,32)/b11-10+/t19-,20-/m1/s1
InChIKey
SEERZIQQUAZTOL-ANMDKAQQSA-N
Cross-matching ID
PubChem CID
446156
ChEBI ID
CHEBI:3558
CAS Number
145599-86-6
UNII
AM91H2KS67
DrugBank ID
DB00439
TTD ID
D03KIA
VARIDT ID
DR00391
INTEDE ID
DR0290
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
HMG-CoA reductase (HMGCR) TTPADOQ HMDH_HUMAN Inhibitor [2]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Sodium/taurocholate cotransporting polypeptide (SLC10A1) DT56EKP NTCP_HUMAN Substrate [7]
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [8]
Organic anion transporting polypeptide 2B1 (SLCO2B1) DTPFTEQ SO2B1_HUMAN Substrate [9]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [10]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [11]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [11]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [12]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [13]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [14]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [15]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [14]
UDP-glucuronosyltransferase 1A3 (UGT1A3) DEF2WXN UD13_HUMAN Substrate [13]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Ryanodine receptor 2 (RYR2) OT0PF19E RYR2_HUMAN Drug Response [6]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification 02 Neoplasm
Disease Class ICD-11: 2C82 Prostate cancer
The Studied Tissue Bone marrow
The Studied Disease Multiple myeloma [ICD-11:2C82]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
HMG-CoA reductase (HMGCR) DTT HMGCR 1.48E-06 1.01 4.34
P-glycoprotein 1 (ABCB1) DTP P-GP 7.42E-01 -4.36E-02 -2.21E-01
P-glycoprotein 1 (ABCB1) DTP P-GP 6.80E-01 2.46E-01 2.41E-01
Organic anion transporting polypeptide 2B1 (SLCO2B1) DTP OATP2B1 1.70E-02 -1.23E+00 -1.37E+00
Organic anion transporting polypeptide 2B1 (SLCO2B1) DTP OATP2B1 4.78E-01 9.86E-02 7.44E-01
Breast cancer resistance protein (ABCG2) DTP BCRP 3.08E-02 -4.06E-01 -8.83E-01
Breast cancer resistance protein (ABCG2) DTP BCRP 7.10E-01 5.87E-03 1.61E-02
Multidrug resistance-associated protein 2 (ABCC2) DTP MRP2 2.22E-01 -1.68E-01 -6.27E-01
Multidrug resistance-associated protein 2 (ABCC2) DTP MRP2 2.44E-01 6.35E-02 3.90E-01
Organic anion transporting polypeptide 1B3 (SLCO1B3) DTP OATP1B3 2.19E-02 4.44E-02 4.09E-01
Organic anion transporting polypeptide 1B3 (SLCO1B3) DTP OATP1B3 6.12E-01 1.16E-01 7.74E-01
Sodium/taurocholate cotransporting polypeptide (SLC10A1) DTP NTCP 1.21E-03 -4.83E-01 -2.00E+00
Sodium/taurocholate cotransporting polypeptide (SLC10A1) DTP NTCP 2.13E-01 1.57E-01 7.50E-01
Organic anion transporting polypeptide 1B1 (SLCO1B1) DTP OATP1B1 1.50E-04 1.94E-01 2.06E+00
Organic anion transporting polypeptide 1B1 (SLCO1B1) DTP OATP1B1 6.86E-01 3.72E-02 2.86E-01
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME UGT1A1 6.60E-01 2.51E-02 8.26E-02
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME UGT1A1 8.62E-03 1.37E-01 8.67E-01
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 7.83E-01 2.87E-03 6.52E-02
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 5.86E-02 -1.69E-01 -8.79E-01
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 2.26E-02 7.10E-02 1.00E+00
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 7.23E-01 -2.28E-02 -3.11E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 2.51E-01 8.39E-02 5.00E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.93E-04 -6.16E-01 -2.64E+00
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Cerivastatin
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Bempedoic acid DM1CI9R Moderate Decreased clearance of Cerivastatin due to the transporter inhibition by Bempedoic acid. Hyper-lipoproteinaemia [5C80] [16]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Cerivastatin and Mipomersen. Hyper-lipoproteinaemia [5C80] [17]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Cerivastatin and Teriflunomide. Hyper-lipoproteinaemia [5C80] [18]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Cerivastatin and BMS-201038. Hyper-lipoproteinaemia [5C80] [19]
Coadministration of a Drug Treating the Disease Different from Cerivastatin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Cerivastatin and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [20]
Midostaurin DMI6E0R Moderate Decreased clearance of Cerivastatin due to the transporter inhibition by Midostaurin. Acute myeloid leukaemia [2A60] [21]
Arn-509 DMT81LZ Moderate Accelerated clearance of Cerivastatin due to the transporter induction by Arn-509. Acute myeloid leukaemia [2A60] [21]
Dronedarone DMA8FS5 Moderate Decreased metabolism of Cerivastatin caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [22]
Nifedipine DMSVOZT Moderate Decreased metabolism of Cerivastatin caused by Nifedipine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [22]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Cerivastatin and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [23]
Voriconazole DMAOL2S Major Decreased metabolism of Cerivastatin caused by Voriconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [24]
Posaconazole DMUL5EW Major Decreased metabolism of Cerivastatin caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [20]
Ciprofloxacin XR DM2NLS9 Moderate Decreased metabolism of Cerivastatin caused by Ciprofloxacin XR mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [22]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Cerivastatin caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [25]
Clarithromycin DM4M1SG Major Decreased metabolism of Cerivastatin caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [26]
Telithromycin DMZ4P3A Major Decreased metabolism of Cerivastatin caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [27]
Ag-221 DMS0ZBI Moderate Decreased clearance of Cerivastatin due to the transporter inhibition by Ag-221. BCR-ABL1-negative chronic myeloid leukaemia [2A41] [20]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Cerivastatin and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [28]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Cerivastatin caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [22]
Tucatinib DMBESUA Moderate Decreased metabolism of Cerivastatin caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [25]
Palbociclib DMD7L94 Moderate Decreased metabolism of Cerivastatin caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [22]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Cerivastatin caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [25]
Lumacaftor DMCLWDJ Moderate Increased metabolism of Cerivastatin caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [29]
Ivacaftor DMZC1HS Moderate Decreased clearance of Cerivastatin due to the transporter inhibition by Ivacaftor. Cystic fibrosis [CA25] [30]
MK-8228 DMOB58Q Moderate Decreased clearance of Cerivastatin due to the transporter inhibition by MK-8228. Cytomegaloviral disease [1D82] [31]
Aprepitant DM053KT Moderate Decreased metabolism of Cerivastatin caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [22]
Vilazodone DM4LECQ Moderate Decreased metabolism of Cerivastatin caused by Vilazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [32]
Nefazodone DM4ZS8M Major Decreased metabolism of Cerivastatin caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [33]
Stiripentol DMMSDOY Moderate Decreased metabolism of Cerivastatin caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [22]
Rufinamide DMWE60C Moderate Increased metabolism of Cerivastatin caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [21]
Itraconazole DMCR1MV Major Decreased metabolism of Cerivastatin caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [24]
Miconazole DMPMYE8 Moderate Decreased metabolism of Cerivastatin caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [21]
Ketoconazole DMPZI3Q Major Decreased metabolism of Cerivastatin caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [24]
Cimetidine DMH61ZB Moderate Decreased metabolism of Cerivastatin caused by Cimetidine mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [22]
Simeprevir DMLUA9D Moderate Decreased clearance of Cerivastatin due to the transporter inhibition by Simeprevir. Hepatitis virus infection [1E50-1E51] [34]
Fostemsavir DM50ILT Moderate Decreased clearance of Cerivastatin due to the transporter inhibition by Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [35]
Cobicistat DM6L4H2 Moderate Decreased clearance of Cerivastatin due to the transporter inhibition by Cobicistat. Human immunodeficiency virus disease [1C60-1C62] [20]
Tipranavir DM8HJX6 Major Decreased metabolism of Cerivastatin caused by Tipranavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [36]
Efavirenz DMC0GSJ Moderate Increased metabolism of Cerivastatin caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [37]
Saquinavir DMG814N Major Decreased metabolism of Cerivastatin caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [36]
Etravirine DMGV8QU Moderate Increased metabolism of Cerivastatin caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [38]
Zalcitabine DMH7MUV Moderate Increased risk of peripheral neuropathy by the combination of Cerivastatin and Zalcitabine. Human immunodeficiency virus disease [1C60-1C62] [39]
Amprenavir DMLMXE0 Major Decreased metabolism of Cerivastatin caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [40]
Darunavir DMN3GCH Major Decreased metabolism of Cerivastatin caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [36]
Atazanavir DMSYRBX Major Decreased metabolism of Cerivastatin caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [36]
Ritonavir DMU764S Major Decreased metabolism of Cerivastatin caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [36]
Levamlodipine DM92S6N Moderate Decreased metabolism of Cerivastatin caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [22]
Verapamil DMA7PEW Moderate Decreased metabolism of Cerivastatin caused by Verapamil mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [22]
Conivaptan DM1V329 Major Decreased metabolism of Cerivastatin caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [41]
Suvorexant DM0E6S3 Moderate Decreased metabolism of Cerivastatin caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [22]
Methotrexate DM2TEOL Moderate Increased risk of hepatotoxicity by the combination of Cerivastatin and Methotrexate. Leukaemia [2A60-2B33] [21]
Crizotinib DM4F29C Moderate Decreased metabolism of Cerivastatin caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [22]
Brigatinib DM7W94S Moderate Increased metabolism of Cerivastatin caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [42]
PF-06463922 DMKM7EW Moderate Increased metabolism of Cerivastatin caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [43]
Selpercatinib DMZR15V Moderate Decreased metabolism of Cerivastatin caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [25]
Idelalisib DM602WT Moderate Decreased metabolism of Cerivastatin caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [44]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Cerivastatin and Clofarabine. Mature B-cell lymphoma [2A85] [45]
Vemurafenib DM62UG5 Moderate Decreased metabolism of Cerivastatin caused by Vemurafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [20]
Danazol DML8KTN Major Decreased metabolism of Cerivastatin caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [25]
Exjade DMHPRWG Moderate Decreased metabolism of Cerivastatin caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [46]
Thalidomide DM70BU5 Moderate Increased risk of peripheral neuropathy by the combination of Cerivastatin and Thalidomide. Multiple myeloma [2A83] [39]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Cerivastatin caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [22]
Nilotinib DM7HXWT Moderate Decreased metabolism of Cerivastatin caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [22]
Imatinib DM7RJXL Moderate Decreased metabolism of Cerivastatin caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [22]
Dasatinib DMJV2EK Moderate Decreased metabolism of Cerivastatin caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [22]
Modafinil DMYILBE Minor Increased metabolism of Cerivastatin caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [47]
Netupitant DMEKAYI Moderate Decreased metabolism of Cerivastatin caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [25]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Cerivastatin caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [22]
Abametapir DM2RX0I Moderate Decreased metabolism of Cerivastatin caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [48]
Lefamulin DME6G97 Moderate Decreased metabolism of Cerivastatin caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [49]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Cerivastatin caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [50]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Cerivastatin caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [18]
Enzalutamide DMGL19D Moderate Increased metabolism of Cerivastatin caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [51]
Darolutamide DMV7YFT Moderate Decreased clearance of Cerivastatin due to the transporter inhibition by Darolutamide. Prostate cancer [2C82] [21]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Cerivastatin and Leflunomide. Rheumatoid arthritis [FA20] [18]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Cerivastatin caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [25]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Cerivastatin caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [21]
Larotrectinib DM26CQR Moderate Decreased metabolism of Cerivastatin caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [25]
Armodafinil DMGB035 Minor Increased metabolism of Cerivastatin caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [47]
Epirubicin DMPDW6T Moderate Increased risk of hepatotoxicity by the combination of Cerivastatin and Epirubicin. Solid tumour/cancer [2A00-2F9Z] [20]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Cerivastatin and Naltrexone. Substance abuse [6C40] [52]
Fostamatinib DM6AUHV Moderate Decreased clearance of Cerivastatin due to the transporter inhibition by Fostamatinib. Thrombocytopenia [3B64] [53]
Brilinta DMBR01X Moderate Decreased metabolism of Cerivastatin caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [22]
Sirolimus DMGW1ID Moderate Increased plasma concentrations of Cerivastatin and Sirolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [54]
Tacrolimus DMZ7XNQ Moderate Increased plasma concentrations of Cerivastatin and Tacrolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [54]
Amiodarone DMUTEX3 Moderate Decreased metabolism of Cerivastatin caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [22]
⏷ Show the Full List of 82 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2950).
2 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011 May;21(5):280-8.
7 Differential effect of genetic variants of Na(+)-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors. Xenobiotica. 2011 Jan;41(1):24-34.
8 Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67.
9 pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1. Mol Pharm. 2011 Aug 1;8(4):1303-13.
10 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
11 FDA Drug Development and Drug Interactions
12 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
13 Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011 May;21(5):280-8.
14 Drug Interactions Flockhart Table
15 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
16 Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
17 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
18 Canadian Pharmacists Association.
19 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
20 Cerner Multum, Inc. "Australian Product Information.".
21 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
22 Agbin NE, Brater DC, Hall SD "Interaction of diltiazem with lovastatin and pravastatin." Clin Pharmacol Ther 61 (1997): 201. [PMID: 9797793]
23 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
24 Akram K, Rao S, Parker M "A lesson for everyone in drug-drug interactions." Int J Cardiol 118 (2007): e19-20. [PMID: 17368833]
25 Andreou ER, Ledger S "Potential drug interaction between simvastatin and danazol causing rhabdomyolysis." Can J Clin Pharmacol 10 (2003): 172-4. [PMID: 14712320]
26 Amsden GW, Kuye O, Wei GC "A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers." J Clin Pharmacol 42 (2002): 444-9. [PMID: 11936570]
27 East C, Alivizatos PA, Grundy SM, Jones PH, Farmer JA "Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation." N Engl J Med 318 (1988): 47-8. [PMID: 3275892]
28 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
29 Cerner Multum, Inc. "Canadian Product Information.".
30 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
31 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
32 Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
33 Alderman CP "Possible interaction between nefazodone and pravastatin." Ann Pharmacother 33 (1999): 871. [PMID: 10466919]
34 Neuvonen PJ, Backman JT, Niemi M "Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin." Clin Pharmacokinet 47 (2008): 463-74. [PMID: 18563955]
35 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
36 Barry M, Mulcahy F, Merry C, Gibbons S, Back D "Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection." Clin Pharmacokinet 36 (1999): 289-304. [PMID: 10320951]
37 Gerber JG, Rosenkranz SL, Fichtenbaum CJ, et al. "Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study." J Acquir Immune Defic Syndr 39 (2005): 307-12. [PMID: 15980690]
38 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
39 Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6. [PMID: 219931]
40 Cheng CH, Miller C, Lowe C, Pearson VE "Rhabdomyolysis due to probable interaction between simvastatin and ritonavir." Am J Health Syst Pharm 59 (2002): 728-30. [PMID: 11977859]
41 Ayanian JZ, Fuchs CS, Stone RM "Lovastatin and rhabdomyolysis." Ann Intern Med 109 (1988): 682-3. [PMID: 3421582]
42 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
43 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
44 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
45 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
46 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
47 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
48 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
49 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
50 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
51 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
52 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
53 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
54 Barshes NR, Goodpastor SE, Goss JA "Sirolimus-atorvastatin drug interaction in the pancreatic islet transplant recipient." Transplantation 76 (2003): 1649-50. [PMID: 14702546]